Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa

Active, not recruiting

• Conditions: Hepatitis B
• Interventions: Drug: Tenofovir disoproxil

• Registration Number: NCT02344498
• Lead Sponsor: Oslo University Hospital

Brief Summary

Viral hepatitis kills nearly one million people each year, even though effective treatment exists. The aim of this study is to establish a treatment protocol for hepatitis B, which is simple and cheap enough to be implemented in resource-limited settings.

Detailed Description

Chronic viral hepatitis is a major health problem globally. Each year nearly one million deaths are attributable to either hepatitis B or C. In Ethiopia 5-10% of the general population are infected with hepatitis B. Oral antiviral treatment of hepatitis B exists, but high costs and advanced laboratory requirements have been barriers to offer such treatment in resource-limited settings, resembling the situation in treatment of HIV/AIDS a decade ago.

The present study will investigate a simplified approach to hepatitis B treatment in resource-limited settings, inspired by the recent success of HIV treatment in such settings. The critical research question is how to identify patients with expected benefit of treatment in the absence of advanced laboratory support. A WHO expert panel recently suggested treatment criteria for use in settings without advanced laboratory facilities, but these criteria have not yet been tested out in real life. The present study will build on and develop the WHO approach to treatment of hepatitis B, aiming to develop a treatment protocol that can be feasible in other resource-limited countries. The potential public health benefit for poor people in low- and middle-income countries is substantial.

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-01-16
• Study First Submitted QC: 2015-01-22
• Study First Posted: 2015-01-26
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-13
• Last Update Posted: 2024-11-15
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 7350

Inclusion Criteria

• Consenting adults (≥18 years) residing in Ethiopia who are HBsAg positive

Exclusion Criteria

• Children <18 years, other terminal disease (cancer etc.)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Urban	Tenofovir disoproxil	HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
Rural	Tenofovir disoproxil	HBV patients in Adama, Afar, Jigjiga and Jimma. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.

Primary Outcome Measures

Name	Time	Method
Death, HCC or decompensated cirrhosis	3 years	Patients will be reviewed every 3-6 months with liver function tests and/or ultrasound to detect the proportion of participants who develop liver decompensation or hepatocellular carcinoma.

Secondary Outcome Measures

Name	Time	Method
Adherence to therapy	3 years	Proportion of patients with \>95% adherence measured by pill count and visual analogue scale
Viral suppression and genotypic resistance	3 years	Proportion of patients with viral load suppression and absence of resistance after \>1 year of antiviral treatment.
Regression of liver inflammation/fibrosis	3 years	Proportion of patients with normalization of ALT and improvement of liver stiffness (by transient elastography)

Trial Locations

Locations (1)

St Paul Hospital Millennium Medical College; 🇪🇹 Addis Abeba, Ethiopia